

Definitive Protocol

Study Title DU 127090; 16 Day Oral (Gavage Administration) Dose Range Finding Study in the Monkey

Study Director R P Jones

Sponsor Solvay Pharmaceuticals B.V.
P.O.Box 900
1380 DA Weesp
The Netherlands

Study Monitor Dr H G Keizer

Performing Laboratory Covance
subcontractors listed in Otley Road, Harrogate
Appendix 3). North Yorkshire HG3 1PY
ENGLAND

Covance Study Number 65/55

Sponsor Number DS 154/484

Page Number 1 of 18

Achieved concentration

Analysis of the formulations for achieved concentration will be performed on the formulation provided for Day 7. The analysis will be performed by Covance. A sample (10ml) from each formulation will be stored frozen (-20°C) for possible future analysis.

TEST SYSTEM

Species, strain and supplier

Sufficient purpose-bred cynomolgus monkeys (*Macaca fascicularis*) will be obtained from Shamrock (GB) in order to provide 4 healthy animals of each sex.

*This document
dated Jan 99*

Specification

The animals will be in the weight range 1.5 to 3 kg on arrival.

Environment

The animals will be housed in an exclusive room, air-conditioned to provide a minimum of 10 air changes/hour. Routinely, the temperature and relative humidity ranges will be 18 to 25°C and 40 to 80% respectively. Fluorescent lighting will be controlled automatically to give a cycle of 12 hours light (0700 to 1900) and 12 hours dark.

The animals will be housed singly during the day in cages of 1.1 m high with a floor area of 0.8 m². Where possible, animals of the same group and sex will be group housed overnight.

Diet and water

Each animal will be offered 100 g of SQC Mazuri Primate Diet (Special Diets Services Ltd., Witham) a 25g Bonio biscuit (Spillers) and a piece of fresh fruit each day after dosing. Any residual food will be removed and estimated in the afternoon. Each batch of diet is analysed for specific constituents and contaminants and contaminants. Typical values are presented in Appendix 1.

Mains water will be provided *ad libitum* via an automatic watering system or bottles. The water is periodically analysed for specific contaminants. Typical values are presented in Appendix 2.

No contaminants are expected to be present in diet or water at levels, which might interfere with achieving the objective of the study.

ANIMAL HEALTH AND WELFARE

All procedures to be carried out on live animals as part of this study will be subject to the provisions of United Kingdom National Law, in particular the Animals (Scientific Procedures) Act, 1986.

In order to monitor the welfare of an individual or group of animals, additional observations to those already detailed may be instigated at the discretion of the Study Director. In certain instances this may include treatment as advised by a Covance animal welfare veterinary surgeon.

PRE-EXPERIMENTAL PROCEDURES

Acclimatisation and health procedures

All animals will be held at the suppliers' premises for a conditioning period. During this time they will be tested for tuberculosis and any prophylactic treatments received will be documented in the study records.

On arrival, all animals will be given a clinical inspection for ill health and tested for tuberculosis if necessary. They will be acclimatised for a period of at least 4 weeks.

A veterinary inspection will be performed before the start of dosing to ensure their suitability for study.

Allocation to treatment group

Not relevant.

of the test system

will be individually identified by electronic implant/tattoo as follows:

Group codes	Identification numbers	
	Male	Female
Pink	1-2	3-4

be appropriately identified with study information including study number number/s.

EXPERIMENTAL OBSERVATIONS

signs

als will be observed throughout the working day for signs of ill health or overt
In addition, each animal will be given a detailed physical examination at
intervals. An individual record will be maintained of the clinical condition of
animal. Post-dosing observations may be performed at the discretion of the Study
or.

idity and mortality

animals will be examined at the beginning and the end of the working day. Any
al which shows marked signs of ill health will be isolated and may be killed and
opsied after consultation with the Study Sponsor.

dy weights

ividual body weights will be recorded on days 1, 4, 8, 12 and before necropsy

ood consumption

he amount of food consumed will be calculated as g/animal/week.

Toxicokinetics

Blood samples (1.5 ml) will be taken from all animals on Days 1, 7 and 10. Samples
will be taken into lithium heparin pre-dose and at 1, 5, 7, 8, 12 and 24 hours post dose.

The plasma will be retained and stored deep frozen (-20°C) prior to despatch to the Sponsors subcontractor, Cephac Bioanalytical Research Center, France (Appendix 7).

TERMINAL PROCEDURES

Necropsy and tissue preservation (Appendix 3)

All animals including decedents will be subject to necropsy.

After an overnight period without food and following sedation with ketamine, an intravenous sodium pentobarbitone overdose will be given prior to exsanguination. A full macroscopic examination will be performed under the general supervision of a pathologist and all lesions will be recorded.

All tissues denoted by (*) from all animals will be preserved in the appropriate fixative/s.

Histopathology (Appendix 3)

No histopathological assessment of tissues will be undertaken in the first instance.

DATA EVALUATION

Data from treated animals will be compared with historical control data.